Stock Price, News, Quote and Profile of EVAXION BIOTECH A/S(NASDAQ:EVAX) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

EVAXION BIOTECH A/S

NASDAQ:EVAX (4/26/2024, 10:03:48 AM)

4.06

-0.06 (-1.46%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap19.54M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Company Info

EVAXION BIOTECH A/S

Bredgade 34E, Copenhagen K

COPENHAGEN 1260

CEO: Lars Staal Webner

Employees: 63

Website: https://www.evaxion-biotech.com/

EVAX News

19 days ago - Evaxion BiotechEvaxion et un collaborateur anonyme annoncent des résultats encourageants concernant les antigènes du vaccin EVX-B1 contre l'infection à staphylocoque doré

Evaxion et son collaborateur ont testé les antigènes du vaccin conçus par Evaxion contre le staphylocoque doré sur un modèle animal cliniquement pertinent...

19 days ago - Evaxion BiotechEvaxion und nicht offengelegter Kooperationspartner veröffentlichen vielversprechende Ergebnisse für EVX-B1-Impfstoff-Antigene gegen Staphylococcus aureus-Infektionen

Evaxion und sein Kooperationspartner testeten die von Evaxion entwickelten Impfstoff-Antigene gegen Staphylococcus aureus in einem klinisch relevanten...

24 days ago - Evaxion BiotechEvaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

a month ago - InvestorPlaceEVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023

EVAX stock results show that Evaxion Biotech met analyst estimates for earnings per share the fourth quarter of 2023.

a month ago - Evaxion BiotechEvaxion Announces Business Update and Full Year 2023 Financial Results

COPENHAGEN, Denmark, March 27, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.

EVAXION BIOTECH A/S (EVAX)

Nasdaq Stock Screener

USA Stock Screener